NeoPharm Co. Ltd. (092730.KQ)

NeoPharm Co. Ltd. (092730.KQ) — VMCI valuation read

Across 120 indicators, NeoPharm Co. Ltd. (092730.KQ) lands at VMCI 72/100. The Consumer Defensive sector median is 50, so the 22-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 092730.KQ in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 092730.KQ trades at 23.0x earnings, 28% above the Consumer Defensive median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Consumer Defensive median (10.0%). On Risk, net debt to EBITDA of 1.8x is the rate-sensitivity line to watch for 092730.KQ on the trailing balance sheet.

092730.KQ fell 3.0% over the trailing 7 days, with a -2.5% read on a 30-day basis.